Prospective Cohort Study of Patients With Infective Endocarditis at Pitié-Salpêtrière Hospital
EIPSL
1 other identifier
observational
700
1 country
1
Brief Summary
Infective endocarditis (IE) is a severe condition associated with high mortality. Due to the relative low prevalence of IE, prospective data are lacking and current guidelines are mostly based on expert consensus with low level of evidence. IE is also associated with severe complications especially strokes that occur in about one third of the patients. In order to improve the management and the prognosis of IE, clinical data from larges prospective cohort studies are needed.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Sep 2020
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
September 15, 2020
CompletedFirst Submitted
Initial submission to the registry
November 5, 2020
CompletedFirst Posted
Study publicly available on registry
August 5, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 1, 2040
ExpectedStudy Completion
Last participant's last visit for all outcomes
March 1, 2041
November 21, 2025
November 1, 2025
20 years
November 5, 2020
November 18, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
All-cause in hospital mortality
All-cause mortality during the length of hospital stay
up to 90 days
Secondary Outcomes (12)
All-cause mortality
an average of 10 years
symptomatic or asymptomatic systemic embolism
up to 90 days after inclusion
Association between coagulation biomarkers (D-dimer, fibrin monomer, circulating anticoagulant, von Willebrandt factor (VWF) antigen level, von Willebrandt factor (VWF) activity) assessed at the inclusion and the presence of systemic embolism
inclusion
Association between coagulation biomarkers (D-dimer, fibrin monomer, circulating anticoagulant, von Willebrandt factor (VWF) antigen level, von Willebrandt factor (VWF) activity) assessed at the inclusion and the presence of systemic embolism
up to 90 days after inclusion
heart failure, intracranial hemorrhage, or false vascular aneurysm during hospitalization
up to 90 days after inclusion
- +7 more secondary outcomes
Eligibility Criteria
All the patients with IE admitted at Cardiology institute of the Pitié-Salpêtrière hospital
You may qualify if:
- Patients with confirmed IE according to European Society of Cardiology criteria
You may not qualify if:
- Opposition of the patient to participate
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
APHP Pitié-Salpêtrière Hospital, Department of Cardiology
Paris, 75013, France
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Nadjib Hammoudi, MD, PhD
Pitié-Salpêtrière Hospital (AP-HP)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Target Duration
- 12 Months
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
November 5, 2020
First Posted
August 5, 2021
Study Start
September 15, 2020
Primary Completion (Estimated)
September 1, 2040
Study Completion (Estimated)
March 1, 2041
Last Updated
November 21, 2025
Record last verified: 2025-11
Data Sharing
- IPD Sharing
- Will not share